coronary tissue engineered vessel

The Humacyte Coronary Tissue Engineered Vessel (CTEV) is an investigational, off-the-shelf, acellular vascular conduit designed for use in coronary artery bypass grafting (CABG) in patients with coronary artery disease. Developed by Humacyte, Inc., the CTEV is manufactured by seeding human vascular smooth muscle cells onto a biodegradable polymer scaffold within a bioreactor. Over several weeks, the cells grow and produce an extracellular matrix (ECM) rich in collagen. The vessel is then decellularized to remove all cellular components and DNA, resulting in a non-immunogenic protein scaffold that can be stored and used without patient-specific matching. Upon implantation, the CTEV is intended to be repopulated by the patient's own cells, effectively transforming into a living, functional blood vessel that integrates with the host tissue. It is regulated as a biological product by the FDA.

Other names

Coronary Human Acellular VesselCoronary HAVHumacyte CTEVHumacyte Coronary Tissue Engineered Vessel